Nanomedicine for the treatment of triple-negative breast cancer

Nanomedicine

Volumn 9, Issue 5, 2014, Pages 561-564

  Kutty, Rajaletchumy Veloo ^a   Wei Leong, David Tai ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

biodegradable polymers; cancer nanotechnology; drug delivery; drug targeting; molecular biomaterials; pharmaceutical nanotechnology

Indexed keywords

CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; DRUG HALF LIFE; ENDOCYTOSIS; FIBROBLAST; HUMAN; MASTECTOMY; MCF 7 CELL LINE; MULTIDRUG RESISTANCE; NANOMEDICINE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; CHEMISTRY; EVIDENCE BASED MEDICINE; FEMALE; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; TRENDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENT; NANOCAPSULE;

ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NANOMEDICINE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84900987002     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.19     Document Type: Review

References (20)

1. Ismail-khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 17(3), 173-176 (2010
2. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13(15), 4429-4434 (2007
3. Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we? Int. J. Cancer 131(11), 2471-2477 (2012
4. Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: Appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 18(3), 165-173 (2011
5. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J. Clin. Oncol. 26(14), 2373-2378 (2008
6. Kyndi M, Sorensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish breast cancer cooperative Group. J. Clin. Oncol. 26(9), 1419-1426 (2008
7. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13(8), 2329-2334 (2007
8. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuVant therapy and long-Term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26(8), 1275-1281 (2008
9. Feng SS, Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 58(18), 4087-4114 (2003
10. Feng SS, Zhao L, Zhang Z et al. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem. Eng. Sci. 62(23), 6641-6648 (2007
11. Kutty RV, Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials 34(38), 10160-10171 (2013
12. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes Res. 2, 14 (2010
13. Tan GR, Feng SS, Leong DT. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. Biomaterials 35(9), 3044-3051 (2013
14. Taurin S, Nehoff H, Diong J et al. Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer. J. Drug Target. 21(7), 675-683 (2013
15. Johnstone TC, Kulak N, Pridgen EM et al. Nanoparticle encapsulation of mitaplatin and the effect there of on in vivo properties. ACS Nano 7(7), 5675-5683 (2013
16. Burke AR, Singh RN, Carroll DL et al. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 33(10), 2961-2970 (2012
17. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors-A new paradigm for cancer therapy. Cancer 94(5), 1593-1611 (2002
18. Milenic DE, Wong KJ, Baidoo KE et al. Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother. Radiopharm. 23(5), 619-631 (2008
19. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33(19), 4889-4906 (2012
20. Mi Y, Guo YJ, Feng SS. Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond.) 7(12), 1291-1294 (2012